AltheaDx Forms Scientific Advisory Board

SAN DIEGO, CA, Apr 29 (MARKET WIRE) --
AltheaDx, a world leader in the development of companion diagnostics and
biopharma services, today announced the formation of their Scientific
Advisory Board with the appointments of four preeminent scientists.

"We are delighted to have assembled such an accomplished group of
scientific leaders as initial appointments to our Scientific Advisory
Board," said David Macdonald, CEO of AltheaDx. "As a group, this Board
will provide solid scientific support for the AltheaDx strategy of
bringing theranostics into clinical use. The Board's collective
experience will serve as a valuable resource as we continue to advance
our pipeline of projects and develop exciting new diagnostic
opportunities and alliances."

AltheaDx provides its customers with a full range of molecular biopharma
services; from biomarker discovery, clinical trial studies, diagnostic
translation, through to reporting clinical results. Appointments to the
AltheaDx Scientific Advisory Board include:

Jorge Leon, Ph.D. -- Chairman of the AltheaDx Scientific Advisory Board
and President, Leomics

Dr. Jorge Leon is internationally recognized for his pioneering work in
molecular diagnostics. Dr. Leon holds a Ph.D. in cellular and molecular
biology from New York University, and completed his postdoctoral studies
at the German Cancer Research Center in Heidelberg and at Columbia
University in NYC. Dr. Leon's subsequent academic research focused on
developing monoclonal antibody-based tumor marker assays and
radio-immuno-imaging devices, which are currently in wide use.

In the early 1990s, Dr. Leon transitioned into industry, playing an
integral role in establishing and leading the molecular diagnostics
laboratories at Quest Diagnostics. As Director of Molecular Diagnostics,
Senior Director of Biotechnology Development, and Vice President of
Applied Genomics, Dr. Leon spent twelve years developing Quest's molecular
diagnostics strategy, which is now the world's largest molecular
diagnostics service laboratory.

Alfred Lui, M.D. -- Medical Director, AltheaDx, Co Founder of Affiliated
Pathologists Medical Group, and President and Chief Executive Officer of
Pathology Inc., a Medical Corporation

Dr. Lui graduated summa cum laude from Andrews University in Michigan. He
attended Loma Linda University Medical School and completed his residency
in Pathology at UCLA-Harbor General Hospital in 1976, following which he
joined the staff of the Liver Unit at the University of Southern
California. In 1979, he joined Dr. Richard Ellis as a co-founder of
Affiliated Pathologists Medical Group. Dr. Lui is a member of Alpha Omega
Alpha National Medical Honour Society and is active in the College of
American Pathologists, where he is a member of the Council on Membership
and Professional Development and on the Publications Committee. He is
currently President and Chief Executive Officer of Pathology Inc., a
Medical Corporation, an independent laboratory performing outpatient
anatomic pathology services. He is the immediate past president and is
currently a member of the board of directors of the California Society of
Pathologists. Dr. Lui has special interests in liver, prostate, and Gyn
pathology.

Dan Mercola, M.D., Ph.D. -- Professor, Pathology and Laboratory Medicine &
Director, Translational Cancer Biology, University of California at Irvine

Dr. Mercola is head of the UCI SPECS consortium, an observational clinical
trial which utilizes prostate tissues and clinical values, to derive gene
signatures predictive of outcome at the time of diagnosis. He is currently
a member of various NIH committees, including Site Visit Review, Program
Project Grant Application, and Ad Hoc Reviewer, in addition to being an
Associate Member at the UCSD Cancer Center, AACR organizing committee, and
various other editorial boards. In 2004, Dr. Mercola was honored as the
"San Diego Padres Medical All-Star" and has closely worked with the
Department of Veterans Affairs and Department of Defense. He has also been
a professor within the Pathology department, and later at the Sidney
Kimmel Cancer Center within UC San Diego. Dr. Mercola did postdoctoral
work at Oxford University after earning a B.S. degree from the University
of Southampton, England and completed his residency at UC San Diego, after
receiving his Ph.D., M.S. and B.A. degrees from UCLA.

Joe Monforte, Ph.D. -- Chief Scientific Officer, AltheaDx

Dr. Monforte has over 20 years' experience with genomics research and
development. Prior to joining AltheaDx, Dr. Monforte served as Chief
Scientific Officer with Althea Technologies. He was also co-founder of
GeneTrace Systems where he served as Chief Scientific Officer. He has held
management roles at the DOE Joint Genome Institute and within the
Toxicology department at SRI International. Dr. Monforte has a Ph.D. in
biophysical chemistry from the University of California, Berkeley.

About AltheaDx

AltheaDx is bringing theranostics into clinical use. The goal of AltheaDx
is to reduce the time and risk of therapeutic development and to provide
high-value testing services. For additional information, please visit:
www.altheadx.com.

Contact:
AltheaDx
Cyrus K. Mirsaidi
Vice President, Business Development
(858) 882-0220 x 325
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-